Clinical trials: Parotid Gland Disorders
Japanese Encephalitis, Measles
Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)
This is a phase IV, randomized, controlled, open-label study proceed in healthy children aged 8 months in China. The primary objective is to demonstrate the immunogenicity of simultaneous administration of JEV-I and MMR is not…
- Conditions
- Japanese Encephalitis, Measles, Mumps, Rubella
- Trial name
- NCT06331702
- Testing
- Vero cell-drived inactive Japanese encephalitis vaccine, Measles-Mumps-Rubella Vaccine
- Where
- China
- Volunteers
- 408 people, healthy volunteers welcome
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
Varicella, Rubella
Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM
The purpose of this study is to assess non-inferiority of two different vaccination regimens using GSK Biological's MMRV vaccine (two doses at 9 and 15 months) or Priorix™ (9 months) and one dose of MMRV vaccine (15 months) to…
- Conditions
- Varicella, Rubella, Mumps, Measles
- Trial name
- NCT00969436
- Testing
- GSK Biological's investigational MMRV vaccine 208136, Priorix™, Varilrix™
- Where
- 6 sites in India
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Mumps, Rubella
Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™
Since measles-mumps-rubella (MMR) and varicella vaccinations are established as routine childhood practice and often co-administered during the second year of life, a combined measles-mumps-rubella-varicella (MeMuRu-OKA) vaccine…
- Conditions
- Mumps, Rubella, Measles, Varicella
- Trial name
- NCT00352898
- Testing
- MeMuRu-OKA (study vac), MMR, Varicella vacc (control)
- Where
- 6 sites in Canada, Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)
This study will compare three consistency lots of ProQuad to each other as well as to M-M-R II and Varivax, administered concomitantly at different injection sites, with respect to immunogenicity, safety, and tolerability.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00985153
- Testing
- Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: Varivax, Comparator: M-M-R II
- Volunteers
- 3,927 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Parotid Neoplasm, Thyroid Neoplasms
Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery
Bevonescein to Highlight Nerves in Patients Undergoing Head \& Neck Surgery
- Conditions
- Parotid Neoplasm, Thyroid Neoplasms, Head and Neck Neoplasms, Surgery
- Trial name
- NCT04420689
- Testing
- Bevonescein
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Alume Biosciences, Inc.
Measles, Mumps
Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)
The purpose of this trial is to study the safety and immune response to measles, mumps, and rubella in children who were vaccinated with an investigational measles-mumps-rubella live vaccine made with artificially made human…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00092404
- Testing
- measles, mumps, and rubella virus vaccine live, Comparator: Measles, Mumps, and Rubella Virus Vaccine Live
- Volunteers
- 1,210 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Measles, Mumps
Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)
Primary objective: To compare if, when given concomitantly with VARIVAX® by the same route at 12-18 months of age using separate injection sites, a single dose of M-M-RTMII administered by IM route is as immunogenic as a single…
- Conditions
- Measles, Mumps, Varicella
- Trial name
- NCT00432523
- Testing
- M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®
- Where
- 2 sites in France, Germany
- Volunteers
- 752 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
This study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
- Trial name
- AQUAx2 (NCT05926765)
- Testing
- AAV2-hAQP1 Concentration 1, AAV2-hAQP1 Concentration 2, AAV2-hAQP1 Concentration 3
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 290 people
- Sponsor
- MeiraGTx, LLC
Mumps
Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants
The purpose of this study is to evaluate the immunogenicity and safety of a live attenuated mumps vaccine in healthy infants between 8 - 18 months old with a commercialized live attenuated mumps vaccine as the control vaccine.
- Trial name
- NCT05065177
- Testing
- Investigational live attenuated mumps vaccine, control live attenuated mumps vaccine
- Where
- China
- Volunteers
- 1,140 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' trivalent MMR (Priorix), comparing it to Merck's MMR vaccine (M-M-R II), which is approved for use in the US in healthy children 12 to 15…
- Trial name
- NCT02184572
- Testing
- Priorix, M-M-R II, Varivax
- Where
- 95 sites in United States, Estonia and 3 more
- Volunteers
- 1,742 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Parotid Diseases
Evaluation of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Parotidectomy Surgery
The objective of the clinical trial is to determine the suitability of the FMwand Ferromagnetic Surgical System for parotidectomy and Head \& Neck surgery.
- Trial name
- NCT02291939
- Testing
- Parotidectomy
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- Domain Surgical, Inc.
Mumps, Influenza
The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students
This study is a randomized, controlled, open-label phase Ⅳ clinical trial of a live attenuated mumps vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
- Trial name
- NCT06208683
- Testing
- Mumps vaccine, Live (MV), Influenza Vaccine, inactivated, quadrivlent(QIV)
- Where
- 3 sites in China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Meningococcal Infections
Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
Safety immune response of Novartis MenACWY-CRM conjugate vaccine when given to healthy toddlers
- Trial name
- NCT00626327
- Testing
- MenACWY-CRM + MMRV, MMRV, MenACWY-CRM
- Where
- 90 sites in United States
- Volunteers
- 1,630 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Rubella, Mumps
Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
To evaluate the safety and immunogenicity of GSK Biologicals' live attenuated MMR vaccine (Priorix) in a local population in Singapore.
- Conditions
- Rubella, Mumps, Measles
- Trial name
- NCT00388440
- Testing
- MMR vaccine (Priorix)
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age
The purpose of this study is to evaluate how consistently 3 different manufacturing lots of the GSK's investigational measles, mumps, rubella, and varicella (MMRVNS) vaccine will produce an immune response.
- Conditions
- Measles, Mumps, Rubella, Varicella (Chickenpox)
- Trial name
- MMRVNS 20-002 (NCT07742644)
- Testing
- MMRVNS vaccine, MMRV vaccine, DTaP-IPV vaccine
- Where
- 62 sites in United States, Argentina and 4 more
- Volunteers
- 1,860 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
ProQuad Dose Selection Study (V221-011)(COMPLETED)
A Study comparing three different doses of ProQuad to concomitant administration of M-M-R II and PUVV (Process Upgrade Varicella Vaccine) vaccines.
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00986232
- Testing
- Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, Comparator: M-M-R II, Comparator: PUVV
- Volunteers
- 1,551 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Mumps
Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine
The purpose of this study is to evaluate the safety and immunogenicity of mumps vaccine in healthy infants aged 8-12months, compared with measles, mumps and rubella combined vaccine, live (MMRV).
- Trial name
- NCT04364399
- Testing
- Mumps vaccine, measles, mumps and rubella combined vaccine, live
- Where
- China
- Volunteers
- 920 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Varicella, Measles
Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)
Primary Objective: To demonstrate that ProQuad® can be administered concomitantly with a booster dose of Infanrix® hexa to healthy children 12 to 23 months of age without impairing either the antibody response rates to measles…
- Conditions
- Varicella, Measles, Mumps, Rubella
- Trial name
- NCT00432042
- Testing
- ProQuad®, Infanrix® hexa
- Where
- 50 sites in Germany, Italy
- Volunteers
- 955 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Meningococcal Meningitis, Measles
Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers
This clinical trial will evaluate the safety of two injections of Menactra® Vaccine in subjects at 9 months and at 12 months of age when the second dose is given concomitantly with other pediatric vaccines routinely administered…
- Conditions
- Meningococcal Meningitis, Measles, Mumps, Rubella
- Trial name
- NCT00483574
- Testing
- Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Measles-mumps-rubella-varicella vaccine, Routine paediatric vaccine - Pneumococcal conjugate (PCV)
- Where
- 79 sites in United States, Chile
- Volunteers
- 1,378 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Mumps, Rubella
Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines
This study will collect data on the safety of the MMRV vaccine (Priorix-Tetra™) used in routine practice in children aged 12 months to 12 years living in the Philippines.
- Conditions
- Mumps, Rubella, Measles, Varicella
- Trial name
- NCT01738841
- Testing
- Priorix-Tetra™, Safety data collection
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline